Last update 02 Jan 2025
Autologous gamma delta T cell therapy (TC BioPharm)
Last update 02 Jan 2025
Overview
Basic Info
Drug Type T-lymphocyte cell therapy |
Synonyms Autologous d T Lymphocytes, Autologous g T Lymphocytes, Autologous T Lymphocytes + [1] |
Target- |
Mechanism Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2/3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with Autologous gamma delta T cell therapy (TC BioPharm)Safety and Efficacy of Ex-vivo Expanded Allogeneic γδ T-lymphocytes (OmnImmune®) in Patients With Active Relapsed or Refractory Acute Myeloid Leukaemia (AML) Who Are Not Eligible for or do Not Consent to High Dose Salvage Chemotherapy and/or Allogeneic Haematopoietic Cell Transplantation (HCT). A Dose Escalation, Open-label, Phase I Study
Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell®) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial
Adoptive immunotherapy using zoledronate-expanded autologous gamma/delta T cells for patients with non-small cell lung cancer refractory to standard treatment. - Zoledronate-expanded autologous gamma/delta T cell therapy for NSCLC
100 Clinical Results associated with Autologous gamma delta T cell therapy (TC BioPharm)
Login to view more data
100 Translational Medicine associated with Autologous gamma delta T cell therapy (TC BioPharm)
Login to view more data
100 Patents (Medical) associated with Autologous gamma delta T cell therapy (TC BioPharm)
Login to view more data
2
Literatures (Medical) associated with Autologous gamma delta T cell therapy (TC BioPharm)25 Oct 2024ORGANIC LETTERS
Cinchona Organocatalyzed Enantioselective Amination for Quaternized Serines as Tertiary Amides
Article
Author: Venter, Gerhard A. ; Hunter, Roger ; Spicer, Christopher D. ; Bhana, Ashlyn D. ; Su, Hong ; Petersen, Wade F. ; Masithi, Phathutshedzo
Herein, we describe a Cinchona-aminocatalyzed enantioselective α-hydrazination of an α-formyl amide for the production of protected quaternized serines as tertiary amides with ee's of generally >98% and ≤99% yields. The proposed TS model supported by density functional theory calculations involves a quinuclidinium ion Brønsted acid-assisted delivery of DtBAD, which occurs from the Re face of an H-bonded enaminone when using a 9S-cinchonamine catalyst, resulting in a hydrazide with the R-configuration as determined by X-ray analysis.
01 Mar 2007The journal of physical chemistry. AQ3 · CHEMISTRY
Geometric Structure of X(AuPH3)4+ (X = N, P, As, Sb): Td or C4v?
Q3 · CHEMISTRY
Article
Author: Fang, Hua ; Wang, Shu-Guang
The geometric structures of X(AuPH3)4+ (X = N, P, As, Sb) compounds have been determined by DFT and ab-initio methods. In agreement with experiment, N(AuPH3)4+ is Td and As(AuPH3)4+ is C4v with an apical As atom. Calculated molecular and experimental crystal structure parameters are compared. The structures of X(AuPH3)4+ (X = P, Sb) are predicted. P(AuPH3)4+ favors Td, as confirmed by CC2. The closed-shell interaction distances of Au...Au from Xalpha are consistent with the experimental values. The electronic structures and chemical deformation densities are analyzed.
100 Deals associated with Autologous gamma delta T cell therapy (TC BioPharm)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Kidney Neoplasms | Phase 3 | GB | - | |
| Melanoma | Phase 3 | GB | - | |
| Non-Small Cell Lung Cancer | Phase 3 | GB | - | |
| Refractory acute myeloid leukemia | Phase 1 | CZ | 27 Nov 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | (LMP2 CTLs) | qquxtmlnzf(nbkddqqbvk) = dupdwmcixj xsqhrhfdgf (xeuxjnehzu ) View more | - | 01 Feb 2009 | ||
(LMP1/2 CTLs) | dzbezkgwgv(quseeupcka) = fvoyfldanz yiwfgbkkta (scyuuxzeef ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free